74
Participants
Start Date
May 16, 2022
Primary Completion Date
August 31, 2026
Study Completion Date
March 31, 2027
VIB4920
Participants will receive 1500 mg of VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
Placebo for VIB4920
Participants will receive placebo for VIB4920 at Weeks 0, 2, 4, 8, 12, 16, 20, and 24 while continuing on MMF and prednisone
NOT_YET_RECRUITING
Hospital for Special Surgery, New York: Division of Rheumatology, New York
RECRUITING
Columbia University Medical Center: Department of Medicine, Division of Rheumatology, New York
RECRUITING
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset
NOT_YET_RECRUITING
Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
NOT_YET_RECRUITING
Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
RECRUITING
University of South Carolina, Charleston
RECRUITING
Emory University School of Medicine: Division of Rheumatology, Atlanta
RECRUITING
University of Miami Miller School of Medicine: Nephrology & Hypertension Division, Miami
NOT_YET_RECRUITING
Ohio State University, Columbus
RECRUITING
University of Chicago, Department of Medicine: Rheumatology, Chicago
RECRUITING
Washington University School of Medicine in St. Louis: Division of Nephrology, St Louis
RECRUITING
University of Colorado School of Medicine: Division of Rheumatology, Aurora
NOT_YET_RECRUITING
UCLA Medical Center: Division of Rheumatology, Los Angeles
NOT_YET_RECRUITING
University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La Jolla
NOT_YET_RECRUITING
University of California, Irvine School of Medicine Division of Rheumatology, Orange
RECRUITING
University of California San Francisco School of Medicine: Lupus Clinic and Rheumatology Clinical Research Center, San Francisco
RECRUITING
Yale University School of Medicine: Section of Rheumatology, New Haven
National Institute of Allergy and Infectious Diseases (NIAID)
NIH